MTOR and neoplasm: Metformin was hypothesized to interfere with insulin-like growth factor signaling by lowering glucose and insulin levels, but also to directly inhibit complex 1 of the respiratory chain in tumor cells with subsequent activation of the adenosine monophosphate kinase (AMPK) and downstream inhibition of the mammalian target of rapamycin (mTOR) [47].